TARS1 and metastatic malignant neoplasm in the lymph nodes: However, our results suggest that TARS1 overexpression is more pronounced in patients with lymph node metastases, independent of HER-2 expression, which is different from the bioinformatic results and requires further validation with larger volume samples.